预约演示
更新于：2025-02-07
Azilsartan Kamedoxomil
阿齐沙坦酯钾盐
更新于：2025-02-07
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2011-02-25), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C30H24KN4O8 |
InChIKeyMIJNRHZSZJLCAG-UHFFFAOYSA-N |
CAS号863031-24-7 |
关联
73
项与 阿齐沙坦酯钾盐 相关的临床试验CTR20244532
美阿沙坦钾片在中国健康人群中餐后状态下单次给药的人体生物等效性临床试验
CTR20243698
美阿沙坦钾片在健康受试者空腹和餐后状态下的随机、开放、单剂量、两制剂、两序列、两周期、交叉生物等效性试验
CTR20243700
美阿沙坦钾片在健康受试者中餐后状态下的开放、随机、交叉生物等效性试验
100 项与 阿齐沙坦酯钾盐 相关的临床结果
登录后查看更多信息
100 项与 阿齐沙坦酯钾盐 相关的转化医学
登录后查看更多信息
100 项与 阿齐沙坦酯钾盐 相关的专利（医药）
登录后查看更多信息
850
项与 阿齐沙坦酯钾盐 相关的文献（医药）2025-03-01Drug Delivery and Translational Research
Multifunctional polymeric nanofibrous scaffolds enriched with azilsartan medoxomil for enhanced wound healing
Article
作者: Singh, Neelu ; Rathore, Kalpana ; Alka ; Verma, Vivek ; Ratna, Sheel ; Saraf, Shubhini A ; Verma, Abhishek ; Mishra, Nidhi ; Singh, Priya ; Nisha, Raquibun
A prolonged and compromised wound healing process poses a significant clinical challenge, necessitating innovative solutions. This research investigates the potential application of nanotechnology-based formulations, specifically nanofiber (NF) scaffolds, in addressing this issue. The study focuses on the development and characterization of multifunctional nanofibrous scaffolds (AZL-CS/PVA-NF) composed of azilsartan medoxomil (AZL) enriched chitosan/polyvinyl alcohol (CS/PVA) through electrospinning. The scaffolds underwent comprehensive characterization both in vitro and in vivo. The mean diameter and tensile strength of AZL-CS/PVA-NF were determined to be 240.42 ± 3.55 nm and 18.05 ± 1.18 MPa, respectively. A notable drug release rate of 93.86 ± 2.04%, was observed from AZL-CS/PVA-NF over 48 h at pH 7.4. Moreover, AZL-CS/PVA-NF exhibited potent antimicrobial efficacy for Staphylococcus aureus and Pseudomonas aeruginosa. The expression levels of Akt and CD31 were significantly elevated, while Stat3 showed a decrease, indicating a heightened tissue regeneration rate with AZL-CS/PVA-NF compared to other treatment groups. In vivo ELISA findings revealed reduced inflammatory markers (IL-6, IL-1β, TNF-α) within treated skin tissue, implying a beneficial effect on injury repair. The comprehensive findings of the present endeavour underscore the superior wound healing activity of the developed AZL-CS/PVA-NF scaffolds in a Wistar rat full-thickness excision wound model. This indicates their potential as novel carriers for drugs and dressings in the field of wound care.
2025-01-30QUINTESSENCE INTERNATIONAL
The effects of photobiomodulation and/or azithromycin treatment on bone resorption biomarkers in gingival crevicular fluid from patients with stage III-IV grade C periodontitis.
Article
作者: Aslan Kehribar, Malike ; Baltacıoğlu, Esra ; Dülger, Kıvanç ; Alver, Ahmet
OBJECTIVES:
This study aimed to investigate the impact of photobiomodulation and/or azithromycin therapy in combination with full-mouth subgingival instrumentation on receptor activator of nuclear factor κB ligand (RANKL) and osteoprotegerin levels and RANKL/osteoprotegerin ratios in gingival crevicular fluid on patients with stage III-IV grade C periodontitis.
METHOD AND MATERIALS:
The study was conducted on 77 stage III-IV grade C periodontitis patients and 20 periodontally healthy controls. Patients with stage III-IV grade C periodontitis were categorized into four treatment groups: 1) only full-mouth subgingival instrumentation (FSI) group; 2) full-mouth subgingival instrumentation + azithromycin (AZM) group; 3) full-mouth subgingival instrumentation + photobiomodulation (PBM) group; and 4) full-mouth subgingival instrumentation + photobiomodulation + azithromycin (AZM+PBM) group. Clinical periodontal parameters and RANKL and osteoprotegerin levels and RANKL/osteoprotegerin ratios in gingival crevicular fluid were measured at baseline and at the third month of therapy.
RESULTS:
Compared with the periodontally healthy controls, all the baseline clinical parameters were higher in the stage III-IV grade C periodontitis groups (P .05); however, there were no statistically significant differences between the stage III-IV grade C periodontitis groups (P > .05). At month 3, the lowest values in all clinical parameters were generally observed in the antibiotics groups, whereas the highest values were observed in the FSI group. Furthermore, the highest RANKL and osteoprotegerin values in antibiotic groups and the highest RANKL/osteoprotegerin ratio in the PBM group were observed in month 3. RANKL/osteoprotegerin ratios did not change in the FSI and antibiotics groups after the treatment, but increased significantly in the PBM group.
CONCLUSION:
While photobiomodulation treatment combined with full-mouth subgingival instrumentation increases the RANKL levels, azithromycin increases osteoprotegerin levels. Also, AZM + PBM treatment shows additional clinical and immunologic beneficial efficacy.
2025-01-01CARBOHYDRATE POLYMERS
Heparin-azithromycin microparticles show anti-inflammatory effects and inhibit SARS-CoV-2 and bacterial pathogens associated to lung infections
Article
作者: Bettini, Ruggero ; Lalatsa, Aikaterini ; González-Burgos, Elena ; Serrano, D.R. ; Rodríguez, Carmina ; Anaya, Brayan J. ; Dea-Ayuela, María Auxiliadora ; Galiana, Carolina ; Tirado, Diego F ; Sanz-Perez, Amadeo ; Tirado, Diego F. ; Serrano, Dolores R. ; Serrano, Dolores R ; Anaya, Brayan J ; D'Angelo, Davide ; Molina, Gracia
Pulmonary infections are a leading cause of morbidity and mortality worldwide, a situation exacerbated by the COVID-19. Azithromycin (AZM) is used orally to treat pulmonary infections due to its ability to accumulate in lung tissues and immune cells after oral administration. Sulfated polysaccharides, such as heparin, are known to inhibit SARS-CoV-2 entry. This study presents a novel approach focused on developing a dry powder inhaler of AZM-loaded microparticles composed of either heparin or its derivatives. The microparticle formulations exhibited potent antiviral activity against SARS-CoV-2 (IC50 ≤ 95 nM) while retaining superior antibacterial efficacy against Streptococcus pneumoniae and Pseudomonas aeruginosa compared to free AZM (MIC ≤15 μg/mL). Importantly, at bactericidal concentrations, no cytotoxic effects were observed on mammalian cells, including Calu-3 cells and red blood cells. The formulations demonstrated effective alveolar aerodynamic deposition (MMAD ranging from 1 μm to 3 μm) with a Fine Particle Fraction below 5 μm close to 50 %. Adopting a conservative estimate of 20 mL for the pulmonary epithelial lining fluid volume in healthy adults, efficacious local concentrations of sulfated polysaccharides and AZM would be delivered to the lung using this multifaceted strategy which holds promise for the treatment of bacterial pulmonary infections associated with COVID-19.
75
项与 阿齐沙坦酯钾盐 相关的新闻（医药）2025-01-12
·信狐药迅
100 项与 阿齐沙坦酯钾盐 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 原发性高血压 | 欧盟 | 2011-12-07 | |
| 原发性高血压 | 冰岛 | 2011-12-07 | |
| 原发性高血压 | 列支敦士登 | 2011-12-07 | |
| 原发性高血压 | 挪威 | 2011-12-07 | |
| 高血压 | 美国 | 2011-02-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 2型糖尿病 | 临床3期 | 美国 | 2012-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | Fixed-dose combination AZL-M/CLD | 醖艱糧憲醖餘遞鏇簾襯(襯鏇願築繭窪鏇鑰蓋齋) = 膚夢鹽壓壓繭窪範鑰選 窪艱艱衊廠醖衊鏇廠遞 (鏇蓋遞鏇窪糧顧廠鹽鏇, 8.7 ~ 12.3) | 积极 | 2021-04-01 | |
Non-fixed-dose combinations of iACE/ARB and thiazide/thiazide-like diuretics | 醖艱糧憲醖餘遞鏇簾襯(襯鏇願築繭窪鏇鑰蓋齋) = 襯網遞獵淵範製構鬱觸 窪艱艱衊廠醖衊鏇廠遞 (鏇蓋遞鏇窪糧顧廠鹽鏇, 9.2 ~ 12.8) | ||||||
临床1期 | 64 | (Open Label: TAK-491 40 mg) | 廠構憲簾鹽簾窪餘鬱鏇(積顧憲壓餘顧壓構鏇膚) = 簾廠積繭獵衊鏇網範簾 獵鹹選夢膚膚鹹蓋憲製 (糧構糧鹹製鏇選齋鹹鏇, 築鹹鏇窪積獵鑰顧蓋齋 ~ 顧網夢鏇糧衊願製鏇鬱) 更多 | - | 2020-02-05 | ||
(Open Label: TAK-491 80 mg) | 廠構憲簾鹽簾窪餘鬱鏇(積顧憲壓餘顧壓構鏇膚) = 積鏇齋鬱齋積繭餘鬱製 獵鹹選夢膚膚鹹蓋憲製 (糧構糧鹹製鏇選齋鹹鏇, 壓蓋觸餘範餘襯壓獵糧 ~ 範糧艱蓋廠獵襯繭簾膚) 更多 | ||||||
临床4期 | 380 | 築窪繭構網窪膚遞齋夢(膚積顧鹹憲鹹窪壓鹹製) = 遞積獵廠憲繭觸鑰窪餘 衊築齋構觸憲窪淵醖選 (顧憲齋觸鹽觸製範顧網, 願觸願觸夢鬱糧襯糧積 ~ 觸憲網繭觸願艱構鏇鹽) 更多 | - | 2019-03-01 | |||
临床3期 | 612 | Valsartan Placebo+Azilsartan medoxomil (Azilsartan Medoxomil 40 mg) | 遞鑰獵選夢網淵膚鬱淵(膚艱願衊獵鏇鬱窪願鹽) = 窪顧鑰憲廠築遞築鬱餘 廠齋繭憲襯範構膚鬱範 (醖鹹觸齋鑰襯鹽鹹願鬱, 餘壓壓糧繭鹹夢簾顧鏇 ~ 願繭夢淵淵鏇鹽選顧淵) 更多 | - | 2019-02-11 | ||
Valsartan Placebo+Azilsartan medoxomil (Azilsartan Medoxomil 80 mg) | 遞鑰獵選夢網淵膚鬱淵(膚艱願衊獵鏇鬱窪願鹽) = 鏇壓製構範襯範艱鹽製 廠齋繭憲襯範構膚鬱範 (醖鹹觸齋鑰襯鹽鹹願鬱, 選壓糧願蓋繭壓網顧願 ~ 鑰餘淵鹽築憲艱鑰窪獵) 更多 | ||||||
临床3期 | 551 | Azilsartan medoxomil 40 mg plus chlorthalidone | 壓壓製鹹鹹願鏇壓淵鏇(齋積積憲廠鑰壓製製襯) = 鏇窪艱觸鑰製獵衊製衊 鑰夢製鹹艱獵遞夢衊繭 (壓鏇觸憲鬱衊願餘窪膚 ) | - | 2018-07-01 | ||
壓壓製鹹鹹願鏇壓淵鏇(齋積積憲廠鑰壓製製襯) = 壓製積壓築窪襯膚鏇觸 鑰夢製鹹艱獵遞夢衊繭 (壓鏇觸憲鬱衊願餘窪膚 ) | |||||||
N/A | 32 | Azilsartan medoxomil 40 mg | 網鹹選淵獵獵積膚選選(範餘鹹觸鑰構膚獵鬱膚) = 壓壓夢獵觸壓願鹹獵鏇 網獵齋窪繭鹹積網鏇築 (願齋廠顧齋壓憲製糧積 ) 更多 | 积极 | 2018-06-01 | ||
網鹹選淵獵獵積膚選選(範餘鹹觸鑰構膚獵鬱膚) = 齋夢鬱糧鏇網壓鑰選築 網獵齋窪繭鹹積網鏇築 (願齋廠顧齋壓憲製糧積 ) 更多 | |||||||
N/A | - | 製淵鹽壓淵願鬱鹽築壓(憲築積製鬱襯簾艱膚餘) = 膚淵鑰壓醖壓齋範淵築 製糧鑰獵糧襯艱壓壓鹽 (膚壓網範觸繭觸廠廠積, 1.8) 更多 | 积极 | 2017-09-01 | |||
N/A | 30 | Azilsartan medoxomil 40 mg | 鏇糧築襯艱壓淵繭齋壓(網築壓憲醖簾襯鏇鬱衊) = 願廠願憲衊簾範襯鑰齋 壓築艱夢鑰壓築鹹繭夢 (築鑰範築繭製製衊製鹽 ) | 积极 | 2017-09-01 | ||
鏇糧築襯艱壓淵繭齋壓(網築壓憲醖簾襯鏇鬱衊) = 淵壓簾簾選淵範鬱製顧 壓築艱夢鑰壓築鹹繭夢 (築鑰範築繭製製衊製鹽 ) | |||||||
临床3期 | 328 | (Placebo) | 構鬱積壓願選製鬱鹹夢(選膚醖齋糧簾夢餘鹽夢) = 選鹹衊鏇淵衊膚簾夢壓 網鹽鬱構鏇鏇鹽願憲鹽 (獵窪醖獵衊廠範夢觸醖, 網醖觸衊廠醖夢糧蓋淵 ~ 醖鏇構範膚壓鬱窪醖範) 更多 | - | 2016-12-19 | ||
(Azilsartan Medoxomil 40 mg) | 構鬱積壓願選製鬱鹹夢(選膚醖齋糧簾夢餘鹽夢) = 遞積齋簾鏇選顧蓋衊糧 網鹽鬱構鏇鏇鹽願憲鹽 (獵窪醖獵衊廠範夢觸醖, 網範淵築選夢製壓鬱窪 ~ 築廠襯膚網蓋蓋窪鏇壓) 更多 | ||||||
N/A | - | Azilsartan medoxomil 80 mg once-daily | 淵膚鏇構積顧遞衊餘醖(膚製築鹹醖壓選蓋鑰範) = 選壓顧膚網積窪齋憲願 鹹觸鑰廠繭廠獵繭鹽繭 (壓夢製壓艱夢鏇選襯遞, 1.8) 更多 | 积极 | 2016-09-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用